A new study from South Africa: Pfizer Inc.’s vaccine provides less immunity to the omicron variant than to other major versions of Covid-19, according to laboratory experiments that indicate a booster may still help stop the highly mutated strain. Researchers at the Africa Health Research Institute in Durban, South Africa found omicron reduces virus-blocking antibodies
The post Study: OMICRON “40-fold” less vaccine effective appeared first on MacroBusiness.
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]